title: Association between an insertion/deletion polymorphism within 3'UTR of SGSM3 and risk of hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy, and multiple host genetic factors are believed to contribute to HCC development. The small G protein signaling modulator 3 (SGSM3) has been shown to be associated with small G protein coupled receptor signal transduction pathway, suggesting a potential role in HCC susceptibility. We carried out a case-control study in a Chinese population (502 cases and 513 controls) to determine whether the 4-bp insertion/deletion polymorphism (rs56228771) in 3' untranslated region of SGSM3 could affect HCC susceptibility. Logistic regression analysis showed that compared with the del/del genotype, the ins/del genotype of rs56228771 was associated with a significantly decreased risk of HCC [adjusted odd ratio = 0.55, 95% confidence interval (CI) = 0.42-0.73, P = 1.93 × 10(-5)]. The combined ins/del + ins/ins genotypes contributed to a 45% decreased HCC risk (95% CI = 0.42-0.73, P = 1.03 × 10(-5)). This protective trend was more prominent in the HBsAg-negative subgroup. Furthermore, in vivo experiments showed that mRNA levels of SGSM3 from HCC tumor tissues and adjacent non-HCC tissues were correlated with rs56228771 genotypes. Tissue samples with ins/ins genotype have the highest level of SGSM3, which are 2.85-3.00-fold and 1.46-1.57-fold higher than that with ins/del and del/del genotype, respectively. Similar results were also observed with four common hepatoma cell lines in vitro. In addition, compared with HCC tissues, significantly higher SGSM3 expression was observed in adjacent non-HCC tissues (fold change = 2.48), implying its tumor suppressor roles in HCC. Bioinformatics prediction showed that the insertion allele disrupted a binding site for microRNA (miRNA)-151-5p, which would upregulate SGSM3. Taken together, we provided initial evidence that rs56228771 may contribute to hepatocarcinogenesis, possibly by affecting SGSM3 expression through a miRNA-mediated regulation. The replication of our studies in other populations and functional analysis will further strengthen the underlining mechanism.
authors.affiliation: Department of Forensic Medicine, Medical College of Soochow University, Suzhou, 215123, Jiangsu, People's Republic of China.
authors.forename: Chaoqun
authors.initials: C
authors.lastname: Wang
authors.forename: Hua
authors.initials: H
authors.lastname: Zhao
authors.forename: Xiankun
authors.initials: X
authors.lastname: Zhao
authors.forename: Jiao
authors.initials: J
authors.lastname: Wan
authors.forename: Dayong
authors.initials: D
authors.lastname: Wang
authors.forename: Wanli
authors.initials: W
authors.lastname: Bi
authors.forename: Xinghong
authors.initials: X
authors.lastname: Jiang
authors.forename: Yuzhen
authors.initials: Y
authors.lastname: Gao
mesh_terms: D020413:3' Untranslated Regions; D000328:Adult; D000483:Alleles; D020029:Base Pairing; D001483:Base Sequence; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D005260:Female; D017353:Gene Deletion; D015870:Gene Expression; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D016254:Mutagenesis, Insertional; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic; D034622:RNA Interference; D012306:Risk
chemical_list: D020413:3' Untranslated Regions; D047908:Intracellular Signaling Peptides and Proteins; D035683:MicroRNAs; C523296:SGSM3 protein, human
references.citation: Trends Cell Biol. 2007 Mar;17(3):118-26
references.pmid: 17197185
references.citation: Clin Liver Dis. 2011 May;15(2):223-43, vii-x
references.pmid: 21689610
references.citation: PLoS Biol. 2004 Nov;2(11):e363
references.pmid: 15502875
references.citation: J Gastroenterol Hepatol. 2011 Jan;26(1):135-44
references.pmid: 21175807
references.citation: Hepatology. 2002 Nov;36(5):1046-9
references.pmid: 12395312
references.citation: Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10350-4
references.pmid: 7937954
references.citation: Mol Cell Biol. 2000 Jul;20(14):5000-9
references.pmid: 10866657
references.citation: OMICS. 2011 Mar;15(3):187-91
references.pmid: 21319996
references.citation: Genes Dev. 2010 Aug 15;24(16):1718-30
references.pmid: 20675406
references.citation: Biotechniques. 1989 Jul-Aug;7(7):736-44
references.pmid: 2483661
references.citation: Eur J Gastroenterol Hepatol. 2005 May;17(5):477-83
references.pmid: 15827436
references.citation: Semin Oncol. 2001 Oct;28(5):441-9
references.pmid: 11685737
references.citation: Genomics. 2007 Aug;90(2):249-60
references.pmid: 17509819
references.citation: Carcinogenesis. 2008 Jul;29(7):1306-11
references.pmid: 18477647
references.citation: RNA. 2005 Dec;11(12):1753-61
references.pmid: 16314451
references.citation: PLoS One. 2013;8(1):e55169
references.pmid: 23359823
references.citation: Biochem Biophys Res Commun. 2004 Dec 17;325(3):774-83
references.pmid: 15541357
references.citation: Carcinogenesis. 2009 Dec;30(12):2064-9
references.pmid: 19917630
references.citation: Curr Drug Targets. 2011 Jul 1;12(8):1188-93
references.pmid: 21561417
references.citation: Nat Cell Biol. 2010 Apr;12(4):390-9
references.pmid: 20305651
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Cancer Res. 2012 Dec 1;72(23):6163-72
references.pmid: 23026137
references.citation: Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58
references.pmid: 20628345
references.citation: Biochim Biophys Acta. 2009 Apr;1795(2):110-6
references.pmid: 19425190
references.citation: J Hepatol. 2010 Feb;52(2):252-7
references.pmid: 20022654
references.citation: Cancer Lett. 2009 Dec 1;286(1):9-14
references.pmid: 19091458